NCT03056326View on ClinicalTrials.gov

A Study to Investigate Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of CHF6333 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

July 31, 2017

Study Completion Date

July 31, 2017

Conditions
Non-Cystic Fibrosis BronchiectasisCystic Fibrosis
Interventions
DRUG

CHF6333 (Part 1 - SAD)

Single doses of CHF6333 at each period

DRUG

Placebo (Part 1 - SAD)

Single doses of placebo matching CHF6333 at each period

DRUG

CHF6333 (Part 2 - MAD)

once daily multiple doses of CHF6333 for 14 days

DRUG

Placebo (Part 2 - MAD)

once daily multiple doses of placebo matching CHF6333 for 14 days

Trial Locations (1)

2060

SGS Life Sciences, Antwerp

All Listed Sponsors
lead

Chiesi Farmaceutici S.p.A.

INDUSTRY

NCT03056326 - A Study to Investigate Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of CHF6333 in Healthy Subjects | Biotech Hunter | Biotech Hunter